nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—breast cancer	0.244	1	CbGaD
Solifenacin—CYP3A4—Exemestane—breast cancer	0.0528	0.133	CbGbCtD
Solifenacin—CYP3A4—Letrozole—breast cancer	0.0449	0.113	CbGbCtD
Solifenacin—CYP3A4—Anastrozole—breast cancer	0.04	0.101	CbGbCtD
Solifenacin—CYP3A4—Toremifene—breast cancer	0.0366	0.0921	CbGbCtD
Solifenacin—CYP3A4—Fulvestrant—breast cancer	0.034	0.0856	CbGbCtD
Solifenacin—CYP3A4—Thiotepa—breast cancer	0.0303	0.0763	CbGbCtD
Solifenacin—CYP3A4—Ixabepilone—breast cancer	0.0277	0.0698	CbGbCtD
Solifenacin—CYP3A4—Lapatinib—breast cancer	0.0267	0.0672	CbGbCtD
Solifenacin—CYP3A4—Raloxifene—breast cancer	0.0202	0.0509	CbGbCtD
Solifenacin—CYP3A4—Vinorelbine—breast cancer	0.0148	0.0373	CbGbCtD
Solifenacin—CYP3A4—Tamoxifen—breast cancer	0.0134	0.0336	CbGbCtD
Solifenacin—CYP3A4—Mitoxantrone—breast cancer	0.013	0.0328	CbGbCtD
Solifenacin—CYP3A4—Paclitaxel—breast cancer	0.0104	0.0262	CbGbCtD
Solifenacin—CYP3A4—Irinotecan—breast cancer	0.0103	0.0258	CbGbCtD
Solifenacin—CYP3A4—Vinblastine—breast cancer	0.00912	0.023	CbGbCtD
Solifenacin—CYP3A4—Docetaxel—breast cancer	0.00752	0.0189	CbGbCtD
Solifenacin—CYP3A4—Doxorubicin—breast cancer	0.00561	0.0141	CbGbCtD
Solifenacin—Benazepril—MTHFR—breast cancer	0.00131	0.608	CrCbGaD
Solifenacin—Mequitazine—CYP2D6—breast cancer	0.000453	0.211	CrCbGaD
Solifenacin—Mequitazine—CYP3A4—breast cancer	0.000389	0.181	CrCbGaD
Solifenacin—Hepatobiliary disease—Methotrexate—breast cancer	0.000118	0.000425	CcSEcCtD
Solifenacin—Hypersensitivity—Mitoxantrone—breast cancer	0.000117	0.000423	CcSEcCtD
Solifenacin—Hypersensitivity—Irinotecan—breast cancer	0.000117	0.000423	CcSEcCtD
Solifenacin—Vomiting—Thiotepa—breast cancer	0.000117	0.000423	CcSEcCtD
Solifenacin—Hypertension—Docetaxel—breast cancer	0.000117	0.00042	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—breast cancer	0.000117	0.00042	CcSEcCtD
Solifenacin—Infestation—Epirubicin—breast cancer	0.000117	0.00042	CcSEcCtD
Solifenacin—Rash—Thiotepa—breast cancer	0.000116	0.00042	CcSEcCtD
Solifenacin—Dermatitis—Thiotepa—breast cancer	0.000116	0.000419	CcSEcCtD
Solifenacin—Headache—Thiotepa—breast cancer	0.000116	0.000417	CcSEcCtD
Solifenacin—Somnolence—Paclitaxel—breast cancer	0.000116	0.000417	CcSEcCtD
Solifenacin—Palpitations—Capecitabine—breast cancer	0.000116	0.000416	CcSEcCtD
Solifenacin—Nausea—Vinorelbine—breast cancer	0.000115	0.000414	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—breast cancer	0.000115	0.000413	CcSEcCtD
Solifenacin—Dyspepsia—Paclitaxel—breast cancer	0.000114	0.000413	CcSEcCtD
Solifenacin—Asthenia—Mitoxantrone—breast cancer	0.000114	0.000412	CcSEcCtD
Solifenacin—Asthenia—Irinotecan—breast cancer	0.000114	0.000412	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000114	0.000412	CcSEcCtD
Solifenacin—Cough—Capecitabine—breast cancer	0.000114	0.000411	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—breast cancer	0.000113	0.000408	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—breast cancer	0.000113	0.000408	CcSEcCtD
Solifenacin—Decreased appetite—Paclitaxel—breast cancer	0.000113	0.000407	CcSEcCtD
Solifenacin—Hypertension—Capecitabine—breast cancer	0.000113	0.000407	CcSEcCtD
Solifenacin—Hypersensitivity—Fluorouracil—breast cancer	0.000112	0.000405	CcSEcCtD
Solifenacin—Dry mouth—Docetaxel—breast cancer	0.000112	0.000405	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000112	0.000405	CcSEcCtD
Solifenacin—Fatigue—Paclitaxel—breast cancer	0.000112	0.000404	CcSEcCtD
Solifenacin—Asthenia—Gemcitabine—breast cancer	0.000111	0.000402	CcSEcCtD
Solifenacin—Constipation—Paclitaxel—breast cancer	0.000111	0.000401	CcSEcCtD
Solifenacin—Confusional state—Docetaxel—breast cancer	0.000111	0.000401	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—breast cancer	0.000111	0.0004	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000111	0.000398	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—breast cancer	0.00011	0.000398	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—breast cancer	0.00011	0.000397	CcSEcCtD
Solifenacin—Anaphylactic shock—Docetaxel—breast cancer	0.00011	0.000397	CcSEcCtD
Solifenacin—Pruritus—Gemcitabine—breast cancer	0.00011	0.000396	CcSEcCtD
Solifenacin—Nausea—Thiotepa—breast cancer	0.00011	0.000395	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—breast cancer	0.00011	0.000395	CcSEcCtD
Solifenacin—Infection—Docetaxel—breast cancer	0.000109	0.000395	CcSEcCtD
Solifenacin—Dry mouth—Capecitabine—breast cancer	0.000109	0.000392	CcSEcCtD
Solifenacin—Nervous system disorder—Docetaxel—breast cancer	0.000108	0.00039	CcSEcCtD
Solifenacin—Pruritus—Fluorouracil—breast cancer	0.000108	0.000389	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—breast cancer	0.000108	0.000389	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—breast cancer	0.000108	0.000389	CcSEcCtD
Solifenacin—Confusional state—Capecitabine—breast cancer	0.000108	0.000388	CcSEcCtD
Solifenacin—Tachycardia—Docetaxel—breast cancer	0.000108	0.000388	CcSEcCtD
Solifenacin—Feeling abnormal—Paclitaxel—breast cancer	0.000107	0.000386	CcSEcCtD
Solifenacin—Skin disorder—Docetaxel—breast cancer	0.000107	0.000386	CcSEcCtD
Solifenacin—Gastrointestinal pain—Paclitaxel—breast cancer	0.000106	0.000383	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—breast cancer	0.000106	0.000382	CcSEcCtD
Solifenacin—Infection—Capecitabine—breast cancer	0.000106	0.000382	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—breast cancer	0.000106	0.000381	CcSEcCtD
Solifenacin—Dizziness—Irinotecan—breast cancer	0.000105	0.00038	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—breast cancer	0.000105	0.000378	CcSEcCtD
Solifenacin—Nervous system disorder—Capecitabine—breast cancer	0.000105	0.000377	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—breast cancer	0.000104	0.000377	CcSEcCtD
Solifenacin—Tachycardia—Capecitabine—breast cancer	0.000104	0.000375	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—breast cancer	0.000104	0.000374	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—breast cancer	0.000104	0.000374	CcSEcCtD
Solifenacin—Skin disorder—Capecitabine—breast cancer	0.000104	0.000374	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—breast cancer	0.000103	0.000372	CcSEcCtD
Solifenacin—Urticaria—Paclitaxel—breast cancer	0.000103	0.000372	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—breast cancer	0.000103	0.000371	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—breast cancer	0.000103	0.000371	CcSEcCtD
Solifenacin—Abdominal pain—Paclitaxel—breast cancer	0.000103	0.00037	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—breast cancer	0.000103	0.00037	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—breast cancer	0.000102	0.000368	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—breast cancer	0.000101	0.000366	CcSEcCtD
Solifenacin—Vomiting—Irinotecan—breast cancer	0.000101	0.000365	CcSEcCtD
Solifenacin—Vomiting—Mitoxantrone—breast cancer	0.000101	0.000365	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—breast cancer	0.000101	0.000364	CcSEcCtD
Solifenacin—Dizziness—Fluorouracil—breast cancer	0.000101	0.000364	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—breast cancer	0.000101	0.000363	CcSEcCtD
Solifenacin—Rash—Mitoxantrone—breast cancer	0.000101	0.000362	CcSEcCtD
Solifenacin—Rash—Irinotecan—breast cancer	0.000101	0.000362	CcSEcCtD
Solifenacin—Dermatitis—Mitoxantrone—breast cancer	0.0001	0.000362	CcSEcCtD
Solifenacin—Dermatitis—Irinotecan—breast cancer	0.0001	0.000362	CcSEcCtD
Solifenacin—Headache—Irinotecan—breast cancer	9.99e-05	0.00036	CcSEcCtD
Solifenacin—Headache—Mitoxantrone—breast cancer	9.99e-05	0.00036	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—breast cancer	9.89e-05	0.000357	CcSEcCtD
Solifenacin—Vomiting—Gemcitabine—breast cancer	9.87e-05	0.000356	CcSEcCtD
Solifenacin—Somnolence—Docetaxel—breast cancer	9.8e-05	0.000353	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—breast cancer	9.79e-05	0.000353	CcSEcCtD
Solifenacin—Rash—Gemcitabine—breast cancer	9.79e-05	0.000353	CcSEcCtD
Solifenacin—Dermatitis—Gemcitabine—breast cancer	9.78e-05	0.000353	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—breast cancer	9.78e-05	0.000352	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—breast cancer	9.73e-05	0.000351	CcSEcCtD
Solifenacin—Headache—Gemcitabine—breast cancer	9.73e-05	0.000351	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—breast cancer	9.71e-05	0.00035	CcSEcCtD
Solifenacin—Vomiting—Fluorouracil—breast cancer	9.71e-05	0.00035	CcSEcCtD
Solifenacin—Dyspepsia—Docetaxel—breast cancer	9.7e-05	0.00035	CcSEcCtD
Solifenacin—Rash—Fluorouracil—breast cancer	9.63e-05	0.000347	CcSEcCtD
Solifenacin—Dermatitis—Fluorouracil—breast cancer	9.62e-05	0.000347	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—breast cancer	9.61e-05	0.000346	CcSEcCtD
Solifenacin—Decreased appetite—Docetaxel—breast cancer	9.58e-05	0.000345	CcSEcCtD
Solifenacin—Hypersensitivity—Paclitaxel—breast cancer	9.58e-05	0.000345	CcSEcCtD
Solifenacin—Headache—Fluorouracil—breast cancer	9.56e-05	0.000345	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—breast cancer	9.56e-05	0.000345	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—breast cancer	9.54e-05	0.000344	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—breast cancer	9.53e-05	0.000344	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Docetaxel—breast cancer	9.51e-05	0.000343	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—breast cancer	9.51e-05	0.000343	CcSEcCtD
Solifenacin—Fatigue—Docetaxel—breast cancer	9.5e-05	0.000342	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—breast cancer	9.49e-05	0.000342	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—breast cancer	9.49e-05	0.000342	CcSEcCtD
Solifenacin—Nausea—Mitoxantrone—breast cancer	9.47e-05	0.000341	CcSEcCtD
Solifenacin—Nausea—Irinotecan—breast cancer	9.47e-05	0.000341	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—breast cancer	9.45e-05	0.000341	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—breast cancer	9.43e-05	0.00034	CcSEcCtD
Solifenacin—Constipation—Docetaxel—breast cancer	9.42e-05	0.00034	CcSEcCtD
Solifenacin—Dyspepsia—Capecitabine—breast cancer	9.39e-05	0.000339	CcSEcCtD
Solifenacin—Asthenia—Paclitaxel—breast cancer	9.33e-05	0.000336	CcSEcCtD
Solifenacin—Decreased appetite—Capecitabine—breast cancer	9.27e-05	0.000334	CcSEcCtD
Solifenacin—Nausea—Gemcitabine—breast cancer	9.22e-05	0.000332	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Capecitabine—breast cancer	9.21e-05	0.000332	CcSEcCtD
Solifenacin—Fatigue—Capecitabine—breast cancer	9.2e-05	0.000332	CcSEcCtD
Solifenacin—Pruritus—Paclitaxel—breast cancer	9.2e-05	0.000332	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—breast cancer	9.17e-05	0.000331	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—breast cancer	9.17e-05	0.00033	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—breast cancer	9.15e-05	0.00033	CcSEcCtD
Solifenacin—Constipation—Capecitabine—breast cancer	9.12e-05	0.000329	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—breast cancer	9.11e-05	0.000328	CcSEcCtD
Solifenacin—Feeling abnormal—Docetaxel—breast cancer	9.08e-05	0.000327	CcSEcCtD
Solifenacin—Nausea—Fluorouracil—breast cancer	9.07e-05	0.000327	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—breast cancer	9.05e-05	0.000326	CcSEcCtD
Solifenacin—Gastrointestinal pain—Docetaxel—breast cancer	9.01e-05	0.000325	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—breast cancer	8.98e-05	0.000324	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—breast cancer	8.92e-05	0.000321	CcSEcCtD
Solifenacin—Feeling abnormal—Capecitabine—breast cancer	8.79e-05	0.000317	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—breast cancer	8.78e-05	0.000317	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—breast cancer	8.74e-05	0.000315	CcSEcCtD
Solifenacin—Gastrointestinal pain—Capecitabine—breast cancer	8.72e-05	0.000314	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—breast cancer	8.72e-05	0.000314	CcSEcCtD
Solifenacin—Abdominal pain—Docetaxel—breast cancer	8.71e-05	0.000314	CcSEcCtD
Solifenacin—Dizziness—Paclitaxel—breast cancer	8.6e-05	0.00031	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—breast cancer	8.58e-05	0.000309	CcSEcCtD
Solifenacin—Cough—Methotrexate—breast cancer	8.49e-05	0.000306	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—breast cancer	8.48e-05	0.000306	CcSEcCtD
Solifenacin—Urticaria—Capecitabine—breast cancer	8.48e-05	0.000306	CcSEcCtD
Solifenacin—Abdominal pain—Capecitabine—breast cancer	8.43e-05	0.000304	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—breast cancer	8.43e-05	0.000304	CcSEcCtD
Solifenacin—Vomiting—Paclitaxel—breast cancer	8.27e-05	0.000298	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—breast cancer	8.25e-05	0.000297	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	8.23e-05	0.000297	CcSEcCtD
Solifenacin—Rash—Paclitaxel—breast cancer	8.2e-05	0.000295	CcSEcCtD
Solifenacin—Dermatitis—Paclitaxel—breast cancer	8.19e-05	0.000295	CcSEcCtD
Solifenacin—Headache—Paclitaxel—breast cancer	8.14e-05	0.000294	CcSEcCtD
Solifenacin—Hypersensitivity—Docetaxel—breast cancer	8.12e-05	0.000293	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—breast cancer	8.05e-05	0.00029	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—breast cancer	8.01e-05	0.000289	CcSEcCtD
Solifenacin—Cough—Epirubicin—breast cancer	7.95e-05	0.000286	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—breast cancer	7.94e-05	0.000286	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—breast cancer	7.94e-05	0.000286	CcSEcCtD
Solifenacin—Asthenia—Docetaxel—breast cancer	7.91e-05	0.000285	CcSEcCtD
Solifenacin—Infection—Methotrexate—breast cancer	7.89e-05	0.000284	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—breast cancer	7.86e-05	0.000283	CcSEcCtD
Solifenacin—Hypersensitivity—Capecitabine—breast cancer	7.86e-05	0.000283	CcSEcCtD
Solifenacin—Pruritus—Docetaxel—breast cancer	7.8e-05	0.000281	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—breast cancer	7.79e-05	0.000281	CcSEcCtD
Solifenacin—Nausea—Paclitaxel—breast cancer	7.72e-05	0.000278	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—breast cancer	7.71e-05	0.000278	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	7.7e-05	0.000278	CcSEcCtD
Solifenacin—Asthenia—Capecitabine—breast cancer	7.65e-05	0.000276	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—breast cancer	7.58e-05	0.000273	CcSEcCtD
Solifenacin—Pruritus—Capecitabine—breast cancer	7.55e-05	0.000272	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—breast cancer	7.49e-05	0.00027	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—breast cancer	7.45e-05	0.000268	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—breast cancer	7.43e-05	0.000268	CcSEcCtD
Solifenacin—Infection—Epirubicin—breast cancer	7.38e-05	0.000266	CcSEcCtD
Solifenacin—Cough—Doxorubicin—breast cancer	7.35e-05	0.000265	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—breast cancer	7.29e-05	0.000263	CcSEcCtD
Solifenacin—Dizziness—Docetaxel—breast cancer	7.29e-05	0.000263	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—breast cancer	7.28e-05	0.000262	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—breast cancer	7.25e-05	0.000261	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—breast cancer	7.22e-05	0.00026	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	7.12e-05	0.000257	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—breast cancer	7.06e-05	0.000255	CcSEcCtD
Solifenacin—Dizziness—Capecitabine—breast cancer	7.05e-05	0.000254	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—breast cancer	7.02e-05	0.000253	CcSEcCtD
Solifenacin—Vomiting—Docetaxel—breast cancer	7.01e-05	0.000253	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—breast cancer	6.99e-05	0.000252	CcSEcCtD
Solifenacin—Rash—Docetaxel—breast cancer	6.95e-05	0.00025	CcSEcCtD
Solifenacin—Dermatitis—Docetaxel—breast cancer	6.94e-05	0.00025	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—breast cancer	6.93e-05	0.00025	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—breast cancer	6.9e-05	0.000249	CcSEcCtD
Solifenacin—Headache—Docetaxel—breast cancer	6.9e-05	0.000249	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—breast cancer	6.88e-05	0.000248	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—breast cancer	6.86e-05	0.000247	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—breast cancer	6.85e-05	0.000247	CcSEcCtD
Solifenacin—Infection—Doxorubicin—breast cancer	6.83e-05	0.000246	CcSEcCtD
Solifenacin—Vomiting—Capecitabine—breast cancer	6.78e-05	0.000245	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—breast cancer	6.74e-05	0.000243	CcSEcCtD
Solifenacin—Rash—Capecitabine—breast cancer	6.73e-05	0.000242	CcSEcCtD
Solifenacin—Dermatitis—Capecitabine—breast cancer	6.72e-05	0.000242	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—breast cancer	6.71e-05	0.000242	CcSEcCtD
Solifenacin—Headache—Capecitabine—breast cancer	6.68e-05	0.000241	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—breast cancer	6.68e-05	0.000241	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—breast cancer	6.61e-05	0.000238	CcSEcCtD
Solifenacin—Nausea—Docetaxel—breast cancer	6.55e-05	0.000236	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—breast cancer	6.54e-05	0.000236	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—breast cancer	6.54e-05	0.000236	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—breast cancer	6.49e-05	0.000234	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—breast cancer	6.46e-05	0.000233	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—breast cancer	6.42e-05	0.000231	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—breast cancer	6.41e-05	0.000231	CcSEcCtD
Solifenacin—Constipation—Epirubicin—breast cancer	6.36e-05	0.000229	CcSEcCtD
Solifenacin—Nausea—Capecitabine—breast cancer	6.34e-05	0.000228	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—breast cancer	6.31e-05	0.000227	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—breast cancer	6.28e-05	0.000226	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—breast cancer	6.12e-05	0.000221	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—breast cancer	6.11e-05	0.00022	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—breast cancer	6.08e-05	0.000219	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—breast cancer	6.05e-05	0.000218	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—breast cancer	5.98e-05	0.000216	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—breast cancer	5.94e-05	0.000214	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—breast cancer	5.93e-05	0.000214	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—breast cancer	5.9e-05	0.000213	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—breast cancer	5.88e-05	0.000212	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—breast cancer	5.88e-05	0.000212	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—breast cancer	5.85e-05	0.000211	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—breast cancer	5.7e-05	0.000205	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—breast cancer	5.67e-05	0.000204	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—breast cancer	5.62e-05	0.000203	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—breast cancer	5.62e-05	0.000203	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—breast cancer	5.48e-05	0.000197	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—breast cancer	5.46e-05	0.000197	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—breast cancer	5.44e-05	0.000196	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—breast cancer	5.33e-05	0.000192	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—breast cancer	5.26e-05	0.00019	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—breast cancer	5.25e-05	0.000189	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—breast cancer	5.07e-05	0.000183	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—breast cancer	5.05e-05	0.000182	CcSEcCtD
Solifenacin—Rash—Methotrexate—breast cancer	5.01e-05	0.000181	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—breast cancer	5e-05	0.00018	CcSEcCtD
Solifenacin—Headache—Methotrexate—breast cancer	4.98e-05	0.000179	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—breast cancer	4.93e-05	0.000178	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—breast cancer	4.91e-05	0.000177	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—breast cancer	4.87e-05	0.000175	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—breast cancer	4.73e-05	0.00017	CcSEcCtD
Solifenacin—Nausea—Methotrexate—breast cancer	4.72e-05	0.00017	CcSEcCtD
Solifenacin—Rash—Epirubicin—breast cancer	4.69e-05	0.000169	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—breast cancer	4.68e-05	0.000169	CcSEcCtD
Solifenacin—Headache—Epirubicin—breast cancer	4.66e-05	0.000168	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—breast cancer	4.55e-05	0.000164	CcSEcCtD
Solifenacin—Nausea—Epirubicin—breast cancer	4.41e-05	0.000159	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—breast cancer	4.37e-05	0.000158	CcSEcCtD
Solifenacin—Rash—Doxorubicin—breast cancer	4.34e-05	0.000156	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—breast cancer	4.33e-05	0.000156	CcSEcCtD
Solifenacin—Headache—Doxorubicin—breast cancer	4.31e-05	0.000155	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—breast cancer	4.08e-05	0.000147	CcSEcCtD
Solifenacin—CHRM3—Metabolism—ALB—breast cancer	6.68e-06	8.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NFKBIA—breast cancer	6.67e-06	8.47e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FN1—breast cancer	6.66e-06	8.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NFKBIA—breast cancer	6.65e-06	8.45e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOTCH1—breast cancer	6.61e-06	8.39e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1B—breast cancer	6.6e-06	8.38e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOTCH1—breast cancer	6.59e-06	8.37e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NFKBIA—breast cancer	6.59e-06	8.36e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCND1—breast cancer	6.57e-06	8.35e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HPGDS—breast cancer	6.56e-06	8.34e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—JUN—breast cancer	6.56e-06	8.33e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—breast cancer	6.53e-06	8.29e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HBA1—breast cancer	6.52e-06	8.28e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOTCH1—breast cancer	6.52e-06	8.28e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CTNNB1—breast cancer	6.51e-06	8.27e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CASP3—breast cancer	6.47e-06	8.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KIT—breast cancer	6.46e-06	8.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CG—breast cancer	6.46e-06	8.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APC—breast cancer	6.46e-06	8.21e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL2—breast cancer	6.46e-06	8.2e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APC—breast cancer	6.44e-06	8.18e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KIT—breast cancer	6.44e-06	8.18e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CG—breast cancer	6.44e-06	8.18e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—breast cancer	6.42e-06	8.16e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—NOS3—breast cancer	6.39e-06	8.12e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGF—breast cancer	6.39e-06	8.11e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—breast cancer	6.38e-06	8.11e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CG—breast cancer	6.38e-06	8.1e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KIT—breast cancer	6.38e-06	8.1e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APC—breast cancer	6.38e-06	8.1e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTT1—breast cancer	6.37e-06	8.09e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ACHE—breast cancer	6.37e-06	8.09e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGF—breast cancer	6.37e-06	8.09e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CDKN1A—breast cancer	6.36e-06	8.08e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTEN—breast cancer	6.34e-06	8.06e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGF—breast cancer	6.3e-06	8.01e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCND1—breast cancer	6.29e-06	8e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—JUN—breast cancer	6.28e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CTNNB1—breast cancer	6.23e-06	7.92e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MAPK8—breast cancer	6.21e-06	7.88e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—breast cancer	6.19e-06	7.86e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—MAPK3—breast cancer	6.19e-06	7.86e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—MAPK3—breast cancer	6.17e-06	7.83e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—breast cancer	6.11e-06	7.76e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—MAPK3—breast cancer	6.11e-06	7.76e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1A—breast cancer	6.09e-06	7.73e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTEN—breast cancer	6.08e-06	7.72e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BRAF—breast cancer	6.07e-06	7.71e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BRAF—breast cancer	6.05e-06	7.69e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP17A1—breast cancer	6.03e-06	7.65e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BRAF—breast cancer	5.99e-06	7.61e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS1—breast cancer	5.97e-06	7.58e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ENO1—breast cancer	5.97e-06	7.58e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MAPK8—breast cancer	5.94e-06	7.55e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—breast cancer	5.93e-06	7.53e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF1—breast cancer	5.92e-06	7.51e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT2—breast cancer	5.91e-06	7.51e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CB—breast cancer	5.9e-06	7.5e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF1—breast cancer	5.9e-06	7.49e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT2—breast cancer	5.89e-06	7.48e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—breast cancer	5.89e-06	7.48e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SRC—breast cancer	5.88e-06	7.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—breast cancer	5.87e-06	7.45e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2D6—breast cancer	5.85e-06	7.43e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—breast cancer	5.85e-06	7.43e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF1—breast cancer	5.84e-06	7.42e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT2—breast cancer	5.84e-06	7.41e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—breast cancer	5.81e-06	7.38e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA2—breast cancer	5.74e-06	7.29e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—breast cancer	5.73e-06	7.28e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CD—breast cancer	5.68e-06	7.21e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STAT3—breast cancer	5.67e-06	7.21e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CD—breast cancer	5.66e-06	7.19e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SRC—breast cancer	5.63e-06	7.16e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	5.63e-06	7.15e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SERPINE1—breast cancer	5.62e-06	7.14e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	5.61e-06	7.12e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CD—breast cancer	5.61e-06	7.12e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SERPINE1—breast cancer	5.6e-06	7.11e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—FASN—breast cancer	5.57e-06	7.07e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—KRAS—breast cancer	5.56e-06	7.06e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	5.55e-06	7.05e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—BCHE—breast cancer	5.55e-06	7.04e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SERPINE1—breast cancer	5.55e-06	7.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—KRAS—breast cancer	5.54e-06	7.04e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—KRAS—breast cancer	5.49e-06	6.97e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—breast cancer	5.49e-06	6.97e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC5A5—breast cancer	5.48e-06	6.96e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STAT3—breast cancer	5.43e-06	6.9e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MAPK3—breast cancer	5.42e-06	6.89e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOS3—breast cancer	5.36e-06	6.81e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOS3—breast cancer	5.35e-06	6.79e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOS3—breast cancer	5.29e-06	6.72e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A1—breast cancer	5.29e-06	6.72e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NQO1—breast cancer	5.29e-06	6.72e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—breast cancer	5.27e-06	6.7e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—breast cancer	5.26e-06	6.68e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MAPK3—breast cancer	5.19e-06	6.59e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—breast cancer	5.16e-06	6.55e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	5.11e-06	6.49e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTEN—breast cancer	5.1e-06	6.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	5.09e-06	6.47e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MDM2—breast cancer	5.09e-06	6.46e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1B1—breast cancer	5.07e-06	6.44e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MDM2—breast cancer	5.07e-06	6.44e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RAF1—breast cancer	5.07e-06	6.44e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RAF1—breast cancer	5.05e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—breast cancer	5.05e-06	6.41e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RELA—breast cancer	5.05e-06	6.41e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	5.04e-06	6.41e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—breast cancer	5.04e-06	6.4e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RELA—breast cancer	5.03e-06	6.39e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MDM2—breast cancer	5.02e-06	6.38e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ERBB2—breast cancer	5.02e-06	6.37e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RAF1—breast cancer	5.01e-06	6.36e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ERBB2—breast cancer	5e-06	6.35e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RELA—breast cancer	4.98e-06	6.33e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HSP90AA1—breast cancer	4.97e-06	6.32e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ERBB2—breast cancer	4.95e-06	6.29e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MTOR—breast cancer	4.95e-06	6.29e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CB—breast cancer	4.95e-06	6.29e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—breast cancer	4.94e-06	6.27e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CB—breast cancer	4.93e-06	6.27e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MTOR—breast cancer	4.93e-06	6.27e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MTOR—breast cancer	4.89e-06	6.21e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CB—breast cancer	4.89e-06	6.21e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KRAS—breast cancer	4.87e-06	6.19e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA1—breast cancer	4.84e-06	6.15e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—STK11—breast cancer	4.77e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP19A1—breast cancer	4.77e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL8—breast cancer	4.76e-06	6.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL8—breast cancer	4.74e-06	6.02e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HRAS—breast cancer	4.73e-06	6e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HRAS—breast cancer	4.71e-06	5.98e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL8—breast cancer	4.7e-06	5.97e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HRAS—breast cancer	4.67e-06	5.93e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KRAS—breast cancer	4.67e-06	5.93e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1B—breast cancer	4.65e-06	5.9e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1B—breast cancer	4.63e-06	5.88e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—breast cancer	4.6e-06	5.84e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1B—breast cancer	4.59e-06	5.83e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—breast cancer	4.58e-06	5.82e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CASP3—breast cancer	4.55e-06	5.78e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL2—breast cancer	4.55e-06	5.78e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CASP3—breast cancer	4.54e-06	5.77e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—breast cancer	4.54e-06	5.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL2—breast cancer	4.53e-06	5.76e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—breast cancer	4.52e-06	5.75e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—breast cancer	4.51e-06	5.73e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CASP3—breast cancer	4.49e-06	5.71e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL2—breast cancer	4.49e-06	5.7e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CA—breast cancer	4.48e-06	5.69e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—breast cancer	4.47e-06	5.67e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—COMT—breast cancer	4.43e-06	5.63e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCND1—breast cancer	4.43e-06	5.63e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—JUN—breast cancer	4.42e-06	5.62e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCND1—breast cancer	4.42e-06	5.61e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTP1—breast cancer	4.41e-06	5.6e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—JUN—breast cancer	4.41e-06	5.6e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CTNNB1—breast cancer	4.39e-06	5.58e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCND1—breast cancer	4.38e-06	5.56e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CTNNB1—breast cancer	4.38e-06	5.56e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—JUN—breast cancer	4.37e-06	5.55e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMOX1—breast cancer	4.35e-06	5.53e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ITPR1—breast cancer	4.34e-06	5.52e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CTNNB1—breast cancer	4.33e-06	5.5e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TP53—breast cancer	4.33e-06	5.5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—breast cancer	4.3e-06	5.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—breast cancer	4.29e-06	5.45e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1A—breast cancer	4.29e-06	5.45e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CA—breast cancer	4.29e-06	5.44e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTEN—breast cancer	4.28e-06	5.43e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1A—breast cancer	4.27e-06	5.43e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTEN—breast cancer	4.26e-06	5.42e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—breast cancer	4.25e-06	5.4e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1A—breast cancer	4.23e-06	5.38e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTEN—breast cancer	4.22e-06	5.36e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK8—breast cancer	4.18e-06	5.32e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ABCB1—breast cancer	4.18e-06	5.31e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—breast cancer	4.17e-06	5.3e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK8—breast cancer	4.17e-06	5.3e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—breast cancer	4.16e-06	5.28e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TP53—breast cancer	4.15e-06	5.27e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HRAS—breast cancer	4.14e-06	5.26e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK8—breast cancer	4.13e-06	5.25e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—breast cancer	4.12e-06	5.23e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TYMS—breast cancer	4.1e-06	5.21e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTM1—breast cancer	4.05e-06	5.15e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOR1—breast cancer	4.05e-06	5.15e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PLA2G4A—breast cancer	4.05e-06	5.15e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SRC—breast cancer	3.97e-06	5.04e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HRAS—breast cancer	3.97e-06	5.04e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—breast cancer	3.96e-06	5.03e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SRC—breast cancer	3.95e-06	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SRC—breast cancer	3.92e-06	4.97e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPX1—breast cancer	3.88e-06	4.93e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—breast cancer	3.86e-06	4.91e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—breast cancer	3.85e-06	4.89e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1A1—breast cancer	3.84e-06	4.88e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STAT3—breast cancer	3.83e-06	4.86e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—breast cancer	3.81e-06	4.84e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STAT3—breast cancer	3.81e-06	4.84e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ERCC2—breast cancer	3.81e-06	4.84e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—breast cancer	3.8e-06	4.82e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STAT3—breast cancer	3.78e-06	4.8e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—breast cancer	3.66e-06	4.64e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK3—breast cancer	3.66e-06	4.64e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK3—breast cancer	3.64e-06	4.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK3—breast cancer	3.61e-06	4.58e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CA—breast cancer	3.6e-06	4.57e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTHFR—breast cancer	3.58e-06	4.55e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—breast cancer	3.56e-06	4.52e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—breast cancer	3.55e-06	4.5e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—breast cancer	3.54e-06	4.5e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—breast cancer	3.54e-06	4.49e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—breast cancer	3.51e-06	4.46e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—breast cancer	3.5e-06	4.45e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—breast cancer	3.5e-06	4.45e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—breast cancer	3.48e-06	4.42e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—breast cancer	3.47e-06	4.4e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—breast cancer	3.43e-06	4.36e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CAV1—breast cancer	3.31e-06	4.2e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KRAS—breast cancer	3.28e-06	4.17e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KRAS—breast cancer	3.27e-06	4.16e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KRAS—breast cancer	3.24e-06	4.12e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CA—breast cancer	3.02e-06	3.83e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CG—breast cancer	3.01e-06	3.82e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CA—breast cancer	3.01e-06	3.82e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CA—breast cancer	2.98e-06	3.78e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—breast cancer	2.94e-06	3.73e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TP53—breast cancer	2.92e-06	3.71e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TP53—breast cancer	2.91e-06	3.7e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TP53—breast cancer	2.88e-06	3.66e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HRAS—breast cancer	2.79e-06	3.55e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HRAS—breast cancer	2.78e-06	3.54e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HRAS—breast cancer	2.76e-06	3.5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—breast cancer	2.67e-06	3.39e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—breast cancer	2.66e-06	3.38e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CD—breast cancer	2.65e-06	3.36e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—breast cancer	2.64e-06	3.35e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—breast cancer	2.61e-06	3.32e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NOS3—breast cancer	2.5e-06	3.17e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—breast cancer	2.47e-06	3.13e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—breast cancer	2.46e-06	3.12e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—breast cancer	2.43e-06	3.09e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CB—breast cancer	2.31e-06	2.93e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—breast cancer	2.29e-06	2.9e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTEN—breast cancer	1.99e-06	2.53e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CA—breast cancer	1.41e-06	1.79e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—breast cancer	1.15e-06	1.46e-05	CbGpPWpGaD
